ACOGF 0.24 Alpha Cognition Inc.
| Range: | 0.1638-0.7398 | Vol Avg: | 145071 | Last Div: | 0 | Changes: | 0.08 |
| Beta: | 3.29 | Cap: | 0.07B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Mon Jun 28 2021 | Empoloyees: | |||
| CUSIP: | CIK: | ISIN: | CA02074J2048 | Country: | CA | ||
| CEO: | Mr. Michael E. McFadden | Website: | https://www.alphacognition.com | ||||
Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Stock Details
Positive 0.26
Alpha Cognition Announces Change of Officer
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACO...
businesswire.com·Thu Oct 03 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow